Enliven Therapeutics Inc. Common Stock (ELVN)

About ELVN

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal gro…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

67

Website

www.enliventherapeutics.com/

Fundamentals

1-day range

$57.77$61.18

Market cap

$3.67B

P/E (trailing)

—

P/E (forward)

-24.74

EPS (trailing)

$-1.67

Dividend yield

—

Beta

0.46

Avg. volume

1.45M

Forecasts

10 analyst ratings

Enliven Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ELVN

  Enliven Therapeutics Inc. Common Stock

  $57.82

  ▼ 4.43%
  Market cap $3.67BP/E —
  $14.79$62.32
• TLX

  Telix Pharmaceuticals Limited American Depositary Shares

  $11.28

  ▼ 0.84%
  Market cap $3.60BP/E —
  $6.28$12.5
• GPCR

  Structure Therapeutics Inc. American Depositary Shares

  $47.38

  ▼ 3.74%
  Market cap $3.74BP/E —
  $18.26$94.9
• ALMS

  Alumis Inc. Common Stock

  $22.38

  ▼ 3.58%
  Market cap $3.54BP/E —
  $3.76$31.35
• IDYA

  IDEAYA Biosciences Inc. Common Stock

  $40.13

  ▼ 3.93%
  Market cap $3.50BP/E —
• VKTX

  Viking Therapeutics Inc. Common Stock

  $32.15

  ▼ 5.05%
  Market cap $3.88BP/E —
  $22.96$43.15
• ARQT

  Arcutis Biotherapeutics Inc. Common Stock

  $23.78

  ▼ 4.38%
  Market cap $3.31BP/E 113.86
  $15.1$31.77

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
  benzinga · 8/18/2026
• Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
  Benzinga · 8/18/2026
• William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating
  Benzinga · 8/18/2026
• Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78
  Benzinga · 8/18/2026
• Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73
  Benzinga · 8/18/2026
• Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82
  Benzinga · 8/6/2026
• Guggenheim Maintains Buy on Enliven Therapeutics, Lowers Price Target to $78
  Benzinga · 8/6/2026
• Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $80
  Benzinga · 8/6/2026
• Enliven Therapeutics Q2 EPS $(0.49) Misses $(0.40) Estimate
  Benzinga · 8/5/2026

• Derynck Mika K · August 4, 2026 · Option Exercise

  20.5K @ $22.47
• Derynck Mika K · August 4, 2026 · Option Exercise

  23.4K @ $14.85
• Derynck Mika K · August 4, 2026 · Option Exercise

  27.6K @ $25.28
• Derynck Mika K · August 4, 2026 · Option Exercise

  87.4K @ $2.48
• Derynck Mika K · August 4, 2026 · Sale

  158.8K @ $60.21
• Hohl Benjamin · July 17, 2026 · Option Exercise

  1.1K @ $2.48
• Hohl Benjamin · July 17, 2026 · Sale

  123 @ $53.87
• Hohl Benjamin · July 17, 2026 · Sale

  2.6K @ $53.38
• Hohl Benjamin · July 17, 2026 · Sale

  2.6K @ $52.32
• Hohl Benjamin · July 17, 2026 · Sale

  369 @ $51.48
• Hohl Benjamin · July 17, 2026 · Sale

  324 @ $49.97
• Collins Helen Louise · July 17, 2026 · Option Exercise

  5.0K @ $2.48
• Collins Helen Louise · July 17, 2026 · Sale

  63 @ $53.92
• Collins Helen Louise · July 17, 2026 · Sale

  2.2K @ $53.42
• Collins Helen Louise · July 17, 2026 · Sale

  2.1K @ $52.39

Institutional Ownership

March 31, 2026

Total shares held

61.77M

Total value held

$2.40B

Institutional holders

170